Tuesday, February 7, 2012

Myasthenia Gravis Therapeutics - Pipeline Assessment and Market Forecasts to 2019

Myasthenia Gravis Therapeutics Market is Forecast to Show Slow Growth Until 2019
GlobalData estimates that the global myasthenia gravis therapeutics market was worth $62.9m in 2011. It is forecast to grow at a Compound Annual Growth Rate (CAGR) of 4.9% over the next eight years to reach $92.2m by 2019. The growth in this market can be attributed to an increase in the myasthenia gravis prevalent population. The increase in the prevalent population is primarily due to a reduction in the mortality rate and the longer life expectancy of myasthenia gravis patients. Although the number of treated patients is increasing, the market is experiencing slow growth due to a lack of efficacious products that can treat the disease as opposed to providing symptomatic relief. The treatment landscape is not going to see any major change in the forecast period due to the lack of promising molecules in the late stage pipeline. The global myasthenia gravis market is expected to remain a low value market during the forecast period due to the domination of generics and off-label drugs.

Current Treatment Options Leave a High Level of Unmet Need
GlobalData`s research indicates that the current treatment options are focused on offering symptomatic relief as opposed to treating the disease. The current treatment landscape consists of acetylcholine esterase (AChE) inhibitors (pyridostigmine bromide), steroid (prednisone) and immunosupressants such as azathioprine, cyclosporin A, and mycophenolate mofetil. The available treatment options are moderately successful in meeting the market demand. Even though the mortality rate has declined significantly after the introduction of these drugs, patient satisfaction is still low as the therapies only target symptoms of the disease. This is the reason for the high unmet need in the myasthenia gravis therapeutics market.

Myasthenia Gravis Therapeutics Forecast Report

Published: January 2012
No. of Pages: 62
: Single User License - US$3995                Corporate User License - US$11985

                                  Request Sample

The Current Pipeline is Weak and No New Molecules with Novel Mechanisms of Action are Expected to Enter the Market During the Forecast Period (2011-2019)
GlobalData’s analysis shows that the current myasthenia gravis therapeutics pipeline is weak. The myasthenia gravis therapeutics pipeline consists of six molecules in the various stages of development.
Phase III contains one molecule, four molecules are in Phase II and one molecule is in the IND filed stage. The late stage pipeline contains only one molecule (prednisone) which is already used as an off label drug for the treatment of myasthenia gravis. The early stage pipeline seems promising, but these drugs are in the early stages of development and will not have an impact on the myasthenia gravis therapeutics market during the forecast period.

The report provides information on the key drivers and challenges of the Myasthenia Gravis Therapeutics market. Its scope includes -
  • Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Myasthenia Gravis Therapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019.
  • Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
  • Analysis of the current and future competition in the seven key countries Myasthenia Gravis Therapeutics market.
  • Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Myasthenia Gravis Therapeutics market.
  • Analysis of key recent licensing and partnership agreements in Myasthenia Gravis Therapeutics market
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global Myasthenia Gravis Therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Myasthenia Gravis Therapeutics market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
  • What’s the next big thing in the global Myasthenia Gravis Therapeutics market landscape? – Identify, understand and capitalize.